Journal of Clinical Virology
Volume 43, Issue 1 , Pages 32-36 , September 2008

Incidence of transaminitis among HIV-infected patients with occult hepatitis B

  • Vincent Lo Re III

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Corresponding Author InformationCorresponding author at: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 711 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA. Tel.: +1 215 573 5964; fax: +1 215 349 5111.
    • ,
  • Benjamin Wertheimer

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
    • ,
  • A. Russell Localio

      Affiliations

    • Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • ,
  • Jay R. Kostman

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • ,
  • Janel Dockter

      Affiliations

    • Gen-Probe Incorporated, San Diego, CA, USA
    • ,
  • Jeffrey M. Linnen

      Affiliations

    • Gen-Probe Incorporated, San Diego, CA, USA
    • ,
  • Cristina Giachetti

      Affiliations

    • Gen-Probe Incorporated, San Diego, CA, USA
    • ,
  • Zachariah Dorey-Stein

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • ,
  • Ian Frank

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • ,
  • Brian L. Strom

      Affiliations

    • Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • ,
  • Robert Gross

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    • Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Received 28 August 2007 ,Revised 21 March 2008 ,Accepted 28 March 2008.

References 

  1. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”?. Hepatology. 2001;34(1):194–203
  2. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–26
  3. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace?. Hepatology. 2001;34(1):204–206
  4. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95(12):3529–3536
  5. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253–1260
  6. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998;17(1):6–13
  7. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9(4):243–257
  8. Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol. 2007;39(2):101–105
  9. Katkov WN, Friedman LS, Cody H, Evans A, Kuo G, Choo QL, et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med. 1991;115(11):882–884
  10. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises.. Normal reference laboratory values, N Engl J Med. 1998;339(15):1063–1072
  11. Kubo S, Tamori A, Ohba K, Shuto T, Yamamoto T, Tanaka H, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci. 2001;46(11):2408–2414
  12. Linnen J, Phelps B. In: Implementation of Procleix Ultrio Assay on the Procleix TIGRIS system: a fully automated Triplex NAT Assay. Presented at IPFA/PEI 12th NAT Workshop on Surveillance and Screening of Bloodborne Pathogens. Bethesda, MD. 2005;
  13. Lo Re V, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):315–320
  14. McCormick MK, Dockter J, Linnen JM, Kolk D, Wu Y, Giachetti C. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J Clin Virol. 2006;36(3):166–176
  15. Nunez M, Rios P, Perez-Olmeda M, Soriano V. Lack of ‘occult’ hepatitis B virus infection in HIV-infected patients. AIDS. 2002;16(15):2099–2101
  16. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17(1):20–29
  17. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102–110
  18. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction?. J Hepatol. 2001;34(3):471–473
  19. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet. 2005;365(9460):638–640
  20. Rosner B. Fundamentals of biostatistics. Pacific Grove: Duxbury; 2000;
  21. Shibata Y, Nakata K, Tsuruta S, Hamasaki K, Hayashida Y, Kato Y, et al. Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Int J Oncol. 1999;14(6):1153–1156
  22. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36(3):869–875
  23. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–486

☆ These results were presented, in part, at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles, CA [Abstract 929].

PII: S1386-6532(08)00125-X

doi: 10.1016/j.jcv.2008.03.030

Journal of Clinical Virology
Volume 43, Issue 1 , Pages 32-36 , September 2008

Article Tools